CD56/NCAM-staining showed thirteen (28.3 %) tumors with extensive expressions (more than half of cells), whereas thirty-three (71.7%) samples demonstrated CD56/NCAM staining in less than half of tumor cells. Here, NCAM1 is linked to neoplasm.